| Control group (n=28) | QLB group (n=28) | P value |
---|---|---|---|
Age (years) | 48.25±11.30 | 47.07±12.05 | 0.707 |
Sex (male/female) | Â | Â | 0.284 |
 Male | 13 (46.43) | 17 (60.71) |  |
 Female | 15 (53.57) | 11 (39.29) |  |
BMI (kg/m2) | 23.61±2.51 | 23.27±3.14 | 0.661 |
ASA (I/II/III) | Â | Â | 0.540 |
 I | 9 (32.14) | 11 (39.29) |  |
 II | 15 (53.57) | 14 (50.00) |  |
 III | 4 (14.29) | 3 (10.71) |  |
Surgical site (left/right) | Â | Â | 0.593 |
 Left | 13 (46.43) | 15 (53.57) |  |
 Right | 15 (53.57) | 13 (46.43) |  |
Surgical duration (min) | 187.68±49.08 | 187.75±53.57 | 0.996 |
Propofol consumption (mg) | 1412.68±449.30 | 1366.25±464.85 | 0.705 |
Remifentanil consumption (μg) | 1778.43±668.74 | 1129.39±310.22* | < 0.001 |
Length of PACU stay (min) | 50.61±16.26 | 47.75±17.23 | 0.526 |
Hospital stay (days) | 6.32±2.06 | 5.82±1.87 | 0.345 |